<DOC>
	<DOC>NCT00643513</DOC>
	<brief_summary>To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.</brief_summary>
	<brief_title>Quality Of Life While Receiving Faslodex</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Histologic and/or cytological proven breast cancer. Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months. Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor. ECOG performance status of ≤ 2 Patient willingness to take part in the programm Life expectancy of more than 6 months. Patient ability to complete a questionnaire. Contraindications for Faslodex therapy Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>QUALITY OF LIFE</keyword>
	<keyword>POSTMENOPAUSAL WOMEN</keyword>
	<keyword>HORMONE RECEPTOR POSITIVE DISSEMINATED BREAST CANCER</keyword>
	<keyword>FASLODEX</keyword>
</DOC>